CLVT — Clarivate Plc stock price, charts and financials

NYSE·Technology·Information Technology Services·UK

Latest market price

1.88

+0.06+3.02%

Overview Short InterestFilings

CLVTQT36Clarivate Plc·NYSE

Overview Short InterestFilings

1.88+3.02%

Loading chart...

Signal & projected range

Insider open-market saleHistorical pattern — not a prediction

Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)

Horizon

Unlock the projected rangeSee where this setup landed historically — with Premium.

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Premium shows the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands ofhistorical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

SIFY+0.19%$15.83 VYX-1.45%$8.13 MGRT-0.79%$94.10 EFOR+1.40%$32.67 WYFI-2.31%$24.06 NABL-34.57%$3.27 AI+1.03%$10.32 BBAI-0.90%$3.24

Snapshot

Index	-	P/E	-	EPS (ttm)	-0.52	Insider Own	45.14%	Shs Outstand	639.66M	Perf Week	-8.08%

Market Cap	1.16B	Forward P/E	2.38	EPS next Y	0.77	Insider Trans	-0.86%	Shs Float	334.75M	Perf Month	-17.27%

Enterprise Value	5.20B	PEG	0.02	EPS next Q	0.18	Inst Own	-	Short Float	16.54%	Perf Quarter	-34.77%

Income	-334.12M	P/S	0.48	EPS this Y	242.50%	Inst Trans	-	Short Ratio	8.36	Perf Half Y	-12.50%

Sales	2.41B	P/B	0.26	EPS next Y	3.34%	ROA	-3.19%	Short Interest	55.38M	Perf YTD	-45.51%

Book/sh	-	P/C	2.03	EPS next 5Y	7.75%	ROE	-7.00%	52W High	4.70 -60.09%	Perf Year	-51.85%

Cash/sh	-	P/FCF	3.55	EPS past 3/5Y	-	ROIC	-0.92%	52W Low	1.71 9.64%	Perf 3Y	-79.73%

Dividend Est.	-	EV/EBITDA	10.83	Sales past 3/5Y	-2.64% 14.38%	Gross Margin	66.82%	Volatility	6.62% 7.84%	Perf 5Y	-92.02%

Dividend TTM	-	EV/Sales	2.16	EPS Y/Y TTM	45.83%	Oper. Margin	-3.51%	ATR (14)	0.18	Perf 10Y	-

Dividend Ex-Date	-	Quick Ratio	0.85	Sales Y/Y TTM	-5.63%	Profit Margin	-13.84%	RSI (14)	37.30	Recom	2.90

Dividend Gr. 3/5Y	-	Current Ratio	0.85	EPS Q/Q	5.56%	SMA20	-14.31%	Beta	1.34	Target Price	2.00

Payout	0.00%	Debt/Eq	0.94	Sales Q/Q	-5.48%	SMA50	-17.91%	Rel Volume	0.45	Prev Close	1.82

Employees	12,000	LT Debt/Eq	0.90	Earnings	Nov 04	SMA200	-32.91%	Avg Volume	6.84M	Price	1.88

IPO Date	Oct 29, 2018	Option/Short	No / Yes	EPS/Sales Surpr.	4.64% -0.41%	Net Debt/EBITDA	8.41	Volume	3,076,388	Change	3.02%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Jul-30-26	Reiterated	Barclays	Underweight	$2.50 → $2.00
Jul-07-26	Reiterated	Barclays	Underweight	$2.50
Jan-08-26	Downgrade	Goldman Sachs	Buy → Neutral	$4.20 → $3.60
Dec-17-25	Downgrade	Morgan Stanley	Equal Weight → Underweight	$3.00
Oct-30-25	Reiterated	Goldman Sachs	Buy	$4.80 → $4.20
Jul-18-25	Downgrade	Jefferies	Buy → Hold
Nov-06-24	Downgrade	William Blair	Outperform → Market Perform
Dec-15-23	Downgrade	Wells Fargo	Equal Weight → Underweight
Sep-08-23	Downgrade	Barclays	Equal Weight → Underweight
Aug-25-23	Downgrade	RBC Capital	Outperform → Sector Perform

Latest News

Aug-06-26

Aug-06-2604:00AM

Clarivate Scales Agentic AI Across Cortellis to Advance Drug Developmentprnewswire.com

Aug-04-26

Aug-04-2603:39AM

Clarivate (CLVT) Price Target Decreased by 13.28% to 2.94Fintel

Jul-31-26

Jul-31-2604:47AM

First Trust Advisors LP Has $13.97 Million Stock Holdings in Clarivate PLC $CLVTdefenseworld.net

Jul-30-26

Jul-30-2603:17PM

Citigroup Maintains Neutral on Clarivate, Lowers Price Target to $2.5Benzinga

Jul-29-26

Jul-29-2604:04PM

Clarivate Q2 Earnings Call Highlightsmarketbeat.com

12:13PM

Clarivate Plc (CLVT) Q2 2026 Earnings Call Transcriptseekingalpha.com

10:31AM

Clarivate (CLVT) Q2 Earnings: Taking a Look at Key Metrics Versus Estimateszacks.com

08:31AM

Clarivate PLC (CLVT) Q2 Earnings and Revenues Beat Estimateszacks.com

06:05AM

Clarivate Appoints Michael Easton as Chief Financial Officerprnewswire.com

06:00AM

Clarivate Reports Second Quarter 2026 Resultsprnewswire.com

Jul-21-26

Jul-21-2607:40AM

Clarivate: Selling, But Still A Continued Leverage OverhangSeekingAlpha

Jul-20-26

Jul-20-2603:00AM

Clarivate RiskMark Wins 2026 CODiE Award for Best AI Tool for Lawyersprnewswire.com

Jul-16-26

Jul-16-2603:00AM

USPTO Launches AI Image Search in Trademark Search System, Powered by Clarivateprnewswire.com

Jul-14-26

Jul-14-2603:02AM

Clarivate Selected by Abes to Modernize French National Academic Library Systemprnewswire.com

Jul-12-26

Jul-12-2601:02AM

Clarivate to Sell Life Sciences Unit to Altaris for $600M, Refocus Core Businessmarketbeat.com

Company

Clarivate Plc operates as a prominent information services and analytics firm, furnishing structured data and insights. Its core mission is to facilitate the discovery, safeguard the intellectual property, and enable the commercialization of scientific research, innovations, and established brands. The company's portfolio includes the extensive Web of Science suite, a collection of essential tools such as Web of Science, InCites, Journal Citation Reports, EndNote, ScholarOne, Converis, Publons, and Kopernio. These are designed to support organizations throughout the entire research lifecycle, from initial planning and funding to execution and utilization. Within the Life Sciences domain, Clarivate provides specialized products like Cortellis and Newport Integrity. These platforms cater to pharmaceutical and biotechnology companies, empowering their research endeavors, supplying vital market intelligence, and facilitating competitive monitoring during the development and launch phases of novel drugs. Its Derwent product line, comprising Derwent Innovation, Techstreet, and IP Professional Services, is dedicated to intellectual property management. These tools enable customers to evaluate the originality of potential products, establish their freedom to operate within design parameters, secure patent protection, analyze the competitive technological landscape, and ensure adherence to essential industry standards. Complementing these, CompuMark delivers trademark screening, search, and monitoring solutions vital for businesses and legal firms. Meanwhile, MarkMonitor empowers enterprises to establish, manage, optimize, and fortify their digital presence. Clarivate's diverse clientele spans government agencies, academic institutions, life science enterprises, and research and development corporations worldwide, with operations across the Americas, Middle East, Africa, Europe, and Asia Pacific regions. The company, initially known as Clarivate Analytics Plc, rebranded to Clarivate Plc in May 2020. It maintains its headquarters in London, United Kingdom.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	TTM —	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021	FY 2020 12/31/2020	FY 2019 12/31/2019	FY 2018 12/31/2018
Total Revenue	2,413	2,455	2,557	—	—	—	—	—	—
Cost of Goods Sold Incl. D&A	801	834	869	—	—	—	—	—	—
Gross Profit	1,612	1,622	1,688	—	—	—	—	—	—
Selling, General and Administrative Excl. Other	707	709	728	—	—	—	—	—	—
Research and Development	0	0	0	—	—	—	—	—	—
Other Operating Expense	990	841	1,235	—	—	—	—	—	—
Operating Income	-85	72	-276	—	—	—	—	—	—
Interest Expense	254	265	283	—	—	—	—	—	—
Unusual Expense	—	—	—	—	—	—	—	—	—
Non-Operating Income (Expense)	0	0	5	—	—	—	—	—	—
Net Income Before Taxes	-339	-194	-554	—	—	—	—	—	—
Income Taxes	-5	7	83	—	—	—	—	—	—
Consolidated Net Income	-334	-201	-637	—	—	—	—	—	—
Net Income From Continuing Operations	-334	-201	-637	—	—	—	—	—	—
Net Income	-334	-201	-637	—	—	—	—	—	—
EPS (Recurring)	-0.52	-0.30	-0.96	—	—	—	—	—	—
EPS (Basic, Before Extraordinaries)	-0.52	-0.30	-0.96	—	—	—	—	—	—
EPS (Diluted)	-0.52	-0.30	-0.96	—	—	—	—	—	—
EBITDA	482	929	457	—	—	—	—	—	—
Other After Tax Adjustments	—	—	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—	—	—
Price To Earnings Ratio	—	—	—	—	—	—	—	—	—
Price To Sales Ratio	0.50	0.92	1.38	—	—	—	—	—	—
Gross Margin	66.80	66.07	66.01	—	—	—	—	—	—
Operating Margin	-3.52	2.93	-10.79	—	—	—	—	—	—
Net Margin	-13.84	-8.19	-24.91	—	—	—	—	—	—
Shares Outstanding	639	673	694	—	—	—	—	—	—
Market Capitalization	1,198	2,248	3,526	—	—	—	—	—	—
Operating Lease Expense	—	—	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Snyder Andrew Miles	Director	Aug 03 '26	Sale	1.94	2,489,618	4,829,859	3,856,597	Aug 05
Veinstein Bar	President, A&G	Dec 01 '25	Sale	3.74	309,902	1,159,033	848,811	Dec 02
Cornick Kenneth L.	Director	Nov 10 '25	Buy	3.45	100,000	345,000	1,100,000	Nov 13
Cornick Kenneth L.	Director	Nov 03 '25	Buy	3.52	225,000	792,000	1,000,000	Nov 03
Cornick Kenneth L.	Director	Oct 31 '25	Buy	3.38	500,000	1,690,000	775,000	Nov 03
Snyder Andrew Miles	Director	Oct 31 '25	Buy	3.33	1,460,000	4,861,800	2,247,510	Nov 03
Cornick Kenneth L.	Director	Aug 01 '25	Buy	3.74	165,000	617,100	275,000	Aug 05
Samson James Gordon	President, IP	Jul 01 '25	Sale	4.53	100,000	453,000	1,271,103	Jul 02
Snyder Andrew Miles	Director	Mar 14 '25	Buy	4.17	237,176	989,024	787,510	Mar 18
Bomba Jane L Okun	Director	Mar 12 '25	Buy	4.03	49,750	200,493	49,750	Mar 14
Pritchett Wendell E.	Director	Mar 03 '25	Buy	4.38	22,857	100,114	71,835	Mar 05
SAHA SAURABH	Director	Mar 03 '25	Buy	4.36	58,275	254,079	82,016	Mar 05
Angelakis Michael J	Director	Nov 22 '24	Buy	5.19	765,000	3,970,350	3,465,000	Nov 22
Angelakis Michael J	Director	Nov 21 '24	Buy	5.19	1,200,000	6,228,000	2,700,000	Nov 22
Angelakis Michael J	Director	Nov 20 '24	Buy	5.11	1,500,000	7,665,000	1,500,000	Nov 22

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.